These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37230799)

  • 1. Soluble Guanylyl Cyclase Activator BI 685509 Reduces Portal Hypertension and Portosystemic Shunting in a Rat Thioacetamide-Induced Cirrhosis Model.
    Jones AK; Chen H; Ng KJ; Villalona J; McHugh M; Zeveleva S; Wilks J; Brilisauer K; Bretschneider T; Qian HS; Fryer RM
    J Pharmacol Exp Ther; 2023 Jul; 386(1):70-79. PubMed ID: 37230799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
    Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
    United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
    Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
    World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats.
    Xie G; Wang X; Wang L; Wang L; Atkinson RD; Kanel GC; Gaarde WA; Deleve LD
    Gastroenterology; 2012 Apr; 142(4):918-927.e6. PubMed ID: 22178212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycyrrhizin Attenuates Portal Hypertension and Collateral Shunting via Inhibition of Extrahepatic Angiogenesis in Cirrhotic Rats.
    Pun CK; Huang HC; Chang CC; Chuang CL; Yen CH; Hsu SJ; Lee FY; Hou MC; Huang YH
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats.
    Shirin H; Sharvit E; Aeed H; Gavish D; Bruck R
    World J Gastroenterol; 2013 Jan; 19(2):241-8. PubMed ID: 23345947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial portal vein ligation plus thioacetamide: a method to obtain a new model of cirrhosis and chronic portal hypertension in the rat.
    Méndez-López M; Méndez M; Sánchez-Patán F; Casado I; Aller MA; López L; Corcuera MT; Alonso MJ; Nava MP; Arias J; Arias JL
    J Gastrointest Surg; 2007 Feb; 11(2):187-94. PubMed ID: 17390171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extrahepatic angiogenesis hinders recovery of portal hypertension and collaterals in rats with cirrhosis resolution.
    Hsu SJ; Tsai MH; Chang CC; Hsieh YH; Huang HC; Lee FY; Chuang CL; Hou MC; Lee SD
    Clin Sci (Lond); 2018 Mar; 132(6):669-683. PubMed ID: 29449343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis.
    Gao JH; Wen SL; Yang WJ; Lu YY; Tong H; Huang ZY; Liu ZX; Tang CW
    PLoS One; 2013; 8(7):e69309. PubMed ID: 23922700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis.
    Reiberger T; Berzigotti A; Trebicka J; Ertle J; Gashaw I; Swallow R; Tomisser A
    Trials; 2023 Apr; 24(1):293. PubMed ID: 37095557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications.
    Kreisel W; Lazaro A; Trebicka J; Grosse Perdekamp M; Schmitt-Graeff A; Deibert P
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
    Boyer-Diaz Z; Aristu-Zabalza P; Andrés-Rozas M; Robert C; Ortega-Ribera M; Fernández-Iglesias A; Broqua P; Junien JL; Wettstein G; Bosch J; Gracia-Sancho J
    J Hepatol; 2021 May; 74(5):1188-1199. PubMed ID: 33278455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabigatran Reduces Liver Fibrosis in Thioacetamide-Injured Rats.
    Lee KC; Hsu WF; Hsieh YC; Chan CC; Yang YY; Huang YH; Hou MC; Lin HC
    Dig Dis Sci; 2019 Jan; 64(1):102-112. PubMed ID: 30288660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis.
    Knorr A; Hirth-Dietrich C; Alonso-Alija C; Härter M; Hahn M; Keim Y; Wunder F; Stasch JP
    Arzneimittelforschung; 2008; 58(2):71-80. PubMed ID: 18412020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease.
    Reinhart GA; Harrison PC; Lincoln K; Chen H; Sun P; Hill J; Qian HS; McHugh MC; Clifford H; Ng KJ; Wang H; Fowler D; Gueneva-Boucheva K; Brenneman JB; Bosanac T; Wong D; Fryer RM; Sarko C; Boustany-Kari CM; Pullen SS
    J Pharmacol Exp Ther; 2023 Mar; 384(3):382-392. PubMed ID: 36507845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
    Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
    J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Induction of experimental splenomegaly with portal hypertension in rats with liver cirrhosis].
    Misawa T
    Nihon Shokakibyo Gakkai Zasshi; 1991 Oct; 88(10):2653-62. PubMed ID: 1758082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amiloride reduces portal hypertension in rat liver cirrhosis.
    Steib CJ; Hennenberg M; Beitinger F; Hartmann AC; Bystron M; De Toni EN; Gerbes AL
    Gut; 2010 Jun; 59(6):827-36. PubMed ID: 20551467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celecoxib attenuates hepatocyte apoptosis by inhibiting endoplasmic reticulum stress in thioacetamide-induced cirrhotic rats.
    Su W; Tai Y; Tang SH; Ye YT; Zhao C; Gao JH; Tuo BG; Tang CW
    World J Gastroenterol; 2020 Jul; 26(28):4094-4107. PubMed ID: 32821072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited.
    Laleman W; Vander Elst I; Zeegers M; Servaes R; Libbrecht L; Roskams T; Fevery J; Nevens F
    Eur J Clin Invest; 2006 Apr; 36(4):242-9. PubMed ID: 16620286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.